These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1405603)

  • 1. Divergent effects of TNF alpha in the adoptive immunotherapy of a murine sarcoma.
    Wagner PD; Shu S; Chang AE
    J Surg Res; 1992 Aug; 53(2):152-7. PubMed ID: 1405603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells.
    Aruga A; Shu S; Chang AE
    Cancer Immunol Immunother; 1995 Nov; 41(5):317-24. PubMed ID: 8536278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T; Bertera S; Chang AE; Shu S
    J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
    Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
    J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T; Chang AE; Shu SY
    J Immunol; 1988 Apr; 140(7):2453-61. PubMed ID: 2450925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of poorly immunogenic tumors with in vitro sensitized cells generated by intratumoral administration of biological response modifiers.
    Mukai S; Kato H; Kimura S; Asai K; Kawahito Y; Inoue M; Yamamura Y; Sano H; Sugino S; Shu S
    Int J Immunopharmacol; 1995 Dec; 17(12):963-71. PubMed ID: 8964655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tumor necrosis factor-alpha on the in vitro maturation of tumor-reactive effector T cells.
    Tanigawa K; Craig RA; Stoolman LM; Chang AE
    J Immunother; 2000; 23(5):528-35. PubMed ID: 11001546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
    Sakai K; Chang AE; Shu S
    Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S; Chou T; Rosenberg SA
    J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells.
    Wahl WL; Sussman JJ; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):242-50. PubMed ID: 8061896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct immunologic specificity of tumor regression mediated by effector cells isolated from immunized and tumor-bearing mice.
    Chang AE; Perry-Lalley DM; Shu S
    Cell Immunol; 1989 May; 120(2):419-29. PubMed ID: 2785860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
    Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
    J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.
    Jicha DL; Mulé JJ; Rosenberg SA
    J Exp Med; 1991 Dec; 174(6):1511-5. PubMed ID: 1744582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.